Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Space Condos to Lift Your Metropolitan Living - 2US EPA will reassess safety of herbicide paraquat, says its chief
- 3Mother and Stepson Rescued After Being Swept Over 6 Miles in Paddleboarding Mishap
- 4How did birds survive while dinosaurs went extinct?
- 5'Stranger Things' Season 5: What's going on with Will Byers? That shocking Volume 1 plot twist, explained.
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- Under pressure at home, Belgium's leader treads a tight rope with EU partners over funds for Ukraine
- New Gaza militia declares war on Hamas: 'Your dirty shoes are more honorable'
- Carina Nebula shines with white-blue stars | Space photo of the day for Jan. 5, 2026
- Holiday weather forecast: Where travelers can expect a wintry mix, flooding and record warmth across the U.S.
- Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
- These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E
- Pick Your Favored kind of soup
- Embrace the Outside: Exercises and Entertainment
